Based on report number:

Relevant gene(s):

Patient diplotype(s):

Patient phenotype(s):

Case 1: Antifungal Therapy

PB is a 57-year-old Caucasian male, who is 6’7”, 230 lbs. PB is currently undergoing chemotherapy treatment, which has drastically impaired his immune system. Due to his current risk of infection, his physician has decided to admit him to the oncology inpatient unit at his local hospital. During rounding PB complains of shortness of breath and chest pain to the hospitalist. After further investigation, it is determined that PB has acquired an invasive aspergillus infection of the lungs. Unfamiliar with current treatment strategies for this type of infection, the hospitalist quickly looks at a drug reference and asks you if voriconazole therapy would be appropriate for this patient. If so, he would like you to dose the patient. Due to earlier concerns with PB’s chemotherapy treatment, pharmacogenomics (PGx) testing has been performed and the results report is available. How would you respond to the hospitalist? What dose would you suggest?

Recommendation:

Note:

Recommendation based on:

Found at: